🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to researchers.

A Global Health Concern

Gonorrhoea infections are on the rise globally, with figures suggesting more than 82 million new cases per year. Notably increased rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the reality of rising global incidence, the spread of superbugs and the highly restricted therapeutic options at this time.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists believe that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in the same week. This medication, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for drug creation. The charitable organization GARDP collaborated with the drug firm Innoviva to develop it.

“This milestone signifies a huge turning point in the management of highly resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Data and Worldwide Availability

According to data published in a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This places it at an similar efficacy with the current standard treatment, which uses a dual-drug approach. The research included nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have shared optimism. Access to a easy-to-administer therapy of this kind is seen as a "game-changer" for gonorrhoea control. This is viewed as essential to lessen the impact of the disease for patients and to prevent the spread of untreatable gonorrhoea worldwide.